New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
06:28 EDTHEBHemispherx's fatigue drug to be reviewed again by FDA, WSJ reports
A potential treatment for chronic fatigue syndrome will be reviewed again this week when an FDA panel looks at Hemispherx Biopharma's (HEB) experimental drug Ampligen, reports the Wall Street Journal. The drug has been in development for chronic fatigue syndrome for about two decades, but in 2009 the FDA refused to approve it, saying clinical studies submitted for approval of the product didn't provide "credible evidence" of the drug's effectiveness. Reference Link
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
08:36 EDTHEBHemispherx affiliates author new publication on Ebola
Subscribe for More Information
October 20, 2014
12:02 EDTHEBHemispherx, Squire Patton Boggs partner to fight Ebola virus
Subscribe for More Information
08:34 EDTHEBHemispherx prevails in federal lawsuit, seeks $1M award for fees, cost
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use